Helen Thackray
Directeur Technique/Scientifique/R&D chez BIOCRYST PHARMACEUTICALS, INC.
Fortune : 2 M $ au 30/06/2024
Postes actifs de Helen Thackray
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 19/03/2021 | - |
| Directeur/Membre du Conseil | 20/09/2019 | 19/03/2021 | |
| Independent Dir/Board Member | 20/09/2019 | 19/03/2021 | |
| Holy Cross Hospital (Maryland) | Corporate Officer/Principal | - | - |
| Gw School of Medicine & Health Sciences | Corporate Officer/Principal | 01/01/2000 | - |
Historique de carrière de Helen Thackray
Anciens postes connus de Helen Thackray
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| IMMUNOGEN, INC. | Directeur/Membre du Conseil | 22/09/2021 | 12/02/2024 |
| Independent Dir/Board Member | 22/09/2021 | 12/02/2024 | |
| GLYCOMIMETICS, INC. | Directeur Technique/Scientifique/R&D | 06/01/2012 | 19/03/2021 |
| Corporate Officer/Principal | 01/01/2006 | 06/01/2012 | |
Biosynexus, Inc.
 Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Biosynexus, Inc. develops and markets pharmaceutical products. The company is headquartered in Rockville, MD. | Corporate Officer/Principal | 01/01/2001 | 01/01/2006 |
| National Center for Health Statistics | Corporate Officer/Principal | - | - |
Formation de Helen Thackray
| Stanford University | Undergraduate Degree |
| Gw School of Medicine & Health Sciences | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 9 |
Opérationnelle
| Corporate Officer/Principal | 5 |
| Chief Tech/Sci/R&D Officer | 2 |
| Director/Board Member | 2 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
| Government | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Biosynexus, Inc.
Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Biosynexus, Inc. develops and markets pharmaceutical products. The company is headquartered in Rockville, MD. | Health Technology |
| Holy Cross Hospital (Maryland) | |
| National Center for Health Statistics | Government |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
- Bourse
- Insiders
- Helen Thackray
- Expérience
